Prevail Therapeutics Announces Pricing of Initial Public Offering

NEW YORK–(BUSINESS WIRE)–Jun. 19, 2019– Prevail Therapeutics Inc. (Nasdaq: PRVL) (Prevail), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative disorders, today...

Prevail Therapeutics Announces IND Active for Phase 1/2 Trial of its Gene Therapy PR001

  NEW YORK–(BUSINESS WIRE)–Jun 4, 2019– Prevail Therapeutics Inc. (Prevail), a gene therapy company developing AAV-based gene therapies for patients with neurodegenerative diseases, today announced the U.S. Food and Drug Administration (FDA) has...

The Michael J. Fox Foundation and The Silverstein Foundation for Parkinson’s with GBA Grant Nearly $3 Million to Studies into Disease’s Most Common Known Genetic Contributor

NEW YORK (February 20, 2019) – The Michael J. Fox Foundation for Parkinson’s Research (MJFF) and The Silverstein Foundation for Parkinson’s with GBA announce nearly $3 million in grants to studies investigating glucocerebrosidase beta acid (GBA)....

January, 2019: Founder Jonathan Silverstein Featured in Denison Magazine

Jonathan Silverstein ’89 has made a career out of investing in potential breakthrough cures. Now he needs to find one for himself.

October, 2018: Second Scientific Advisory Board Meeting Gathers Global Thought Leaders

New York, NY – Our Scientific Advisory Board, along with many invited guests from around the globe, gathered on October 26th, 2018 to brainstorm and vet dozens of novel ideas and proposals.